Several studies suggest that both PR and ER expression were biomarkers of sensitivity to endocrine therapy, while recently, some arguments have emerged for the morphological and molecular features of ER-/PR+ BC are close to triple-negative BC (27, 28). The gene discussed is ESR1; the disease is breast cancer.